Dolciami D, Gargaro M, Cerra B, et al. Binding Mode and Structure-Activity Relationships of ITE as an Aryl Hydrocarbon Receptor (AhR) Agonist. ChemMedChem. 2018;13(3):270-279. doi:10.1002/cmdc.201700669
Nagaraja AK, Bass AJ. Hitting the Target in BRAF-Mutant Colorectal Cancer. J Clin Oncol. 2015;33(34):3990-2. doi:10.1200/JCO.2015.63.7793
Kim KH, Kim W, Howard TP, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med. 2015;21(12):1491-6. doi:10.1038/nm.3968
Kim SY, Dunn IF, Firestein R, et al. CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One. 2010;5(2):e8979. doi:10.1371/journal.pone.0008979
Luo C, Lim JH, Lee Y, et al. A PGC1α-mediated transcriptional axis suppresses melanoma metastasis. Nature. 2016;537(7620):422-426. doi:10.1038/nature19347
Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev. 2009;23(18):2152-65. doi:10.1101/gad.1820109
Rozenman MM, Kanan MW, Liu DR. Development and initial application of a hybridization-independent, DNA-encoded reaction discovery system compatible with organic solvents. J Am Chem Soc. 2007;129(48):14933-8. doi:10.1021/ja074155j
Fomina-Yadlin D, Kubicek S, Vetere A, et al. GW8510 increases insulin expression in pancreatic alpha cells through activation of p53 transcriptional activity. PLoS One. 2012;7(1):e28808. doi:10.1371/journal.pone.0028808
Huillard E, Hashizume R, Phillips JJ, et al. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012;109(22):8710-5. doi:10.1073/pnas.1117255109
Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-4. doi:10.1038/nature11183